Filing Flows › Lexicon Pharmaceuticals (LXRX) › Recalls, complaints & regulation
Lexicon Pharmaceuticals (LXRX): EPA violations and clinical trials
Lexicon Pharmaceuticals (LXRX) beyond its filings: 0 EPA-regulated facilities in violation, $10K in penalties over five years; 1 active clinical trial.
Lexicon Pharmaceuticals' latest quarter
Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
Questions
Has Lexicon Pharmaceuticals been fined by the EPA?
The 5 EPA-regulated facilities on file under its name drew $10K in penalties over five years; 0 are in violation now.
How many clinical trials does Lexicon Pharmaceuticals have?
1 active study on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.